glp 1 for cardiovascular The Physiology of Glucagon-like Peptide-1 Receptor Agonists: From Macro-Level Outcomes to Micro-Level Mechanisms Stopping GLP-1 drugs can quickly

5-Amino-1MQ works through metabolic pathways, not hunger signals or nervous system stimulation

Platelet rich plasma and the PACKS-4 platelet aggregation instrument was used with the agonists of inducers EPI (final concentration of 200 M), ADP (final concentration of 10.0 M), AA (final concentration of 2.5 g/mL), and collagen (final concentration of 5.0 g/mL)

doi: 10.3389/fphys.2018.00044 Received 02 October 2017 Accepted 12 January 2018 Published 05 February 2018 Volume 9 - 2018 Edited by Paolo Bernardi, Universit degli Studi di Padova, Italy Reviewed by Amadou K

In addition to 5-amino-1MQ, JBSNF-000088 is another NNMT inhibitor that is promising for treatment of obesity and associated T2D